Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma

Biomedicine and Pharmacotherapy

Volumn 102, Issue , 2018, Pages 653-669

  Toraih, Eman A ^a   Ellawindy, Alia ^a   Fala, Salma Y ^a   Al Ageeli, Essam ^b   Gouda, Nawal S ^c   Fawzy, Manal S ^a,d   Hosny, Somaya ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b JAZAN UNIVERSITY   (Saudi Arabia)

^c MANSOURA UNIVERSITY   (Egypt)

^d NORTHERN BORDER UNIVERSITY   (Saudi Arabia)

Author keywords

HCC; HCV; lncRNA; MALAT1; Meta analysis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; LONG NONCODING RNA MALAT1; LONG UNTRANSLATED RNA; UNCLASSIFIED DRUG; ALPHA FETOPROTEIN; MALAT1 LONG NON-CODING RNA, HUMAN; MESSENGER RNA; TRANSCRIPTOME;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION PROFILING; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR NUMBER; AGED; BLOOD; CARCINOGENESIS; CASE CONTROL STUDY; COMPUTER SIMULATION; DEMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; LIVER CIRRHOSIS; LIVER TUMOR; META ANALYSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PUBLISHING; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COMPUTER SIMULATION; DEMOGRAPHY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PUBLICATION BIAS; RNA, LONG NONCODING; RNA, MESSENGER; TRANSCRIPTOME;

EID: 85044603788     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.03.105     Document Type: Article

References (87)

1. Shen, S., Lin, Y., Yuan, X., Shen, L., Chen, J., Chen, L., et al. Biomarker MicroRNAs for diagnosis, prognosis and treatment of hepatocellular carcinoma: A functional survey and comparison. Sci. Rep., 6, 2016, 38311, 10.1038/srep38311.
2. He, S., Zhang, D.C., Wei, C., MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. Clin. Res. Hepatol. Gastroenterol. 39 (2015), 426–434, 10.1016/j.clinre.2015.01.006.
3. Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., Sirlin, C.B., Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (N.Y.)., 2017, 10.1007/s00261-017-1209-1.
4. Jin, K., Li, T., Sánchez-Duffhues, G., Zhou, F., Zhang, L., Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget 8 (2017), 22145–22165, 10.18632/oncotarget.13530.
5. Demerdash, H.M., Hussien, H.M., Hassouna, E., Arida, E.A., Detection of MicroRNA in hepatic cirrhosis and hepatocellular carcinoma in hepatitis C genotype-4 in Egyptian patients. Biomed. Res. International., 2017, 2017, 1806069, 10.1155/2017/1806069.
6. VC-Y, Sun, Sarna, L., Symptom management in hepatocellular carcinoma. Clin. J. Oncol. Nurs. 12 (2008), 759–766, 10.1188/08.CJON.759-766.
7. Quagliata, L., Terracciano, L.M., Liver Diseases and Long Non-Coding RNAs: New Insight and Perspective. Front Med., 1, 2014, 35, 10.3389/fmed.2014.00035.
8. Hosseini, E.S., Meryet-Figuiere, M., Sabzalipoor, H., Kashani, H.H., Nikzad, H., Asemi, Z., Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol. Cancer., 16(107), 2017, 10.1186/s12943-017-0671-2.
9. Bozgeyik, E., Bayraktar, E., Chavez-Reyes, A., Rodriguez-Aguayo, C., OncoLncs: Long non-coding RNAs with oncogenic functions. Mol. Biol., 5(162), 2016, 10.4172/2168-9547.1000162.
10. Takahashi, K., Yan, I., Haga, H., Patel, T., Long non-coding RNA in liver diseases. Hepatology 60 (2014), 744–753.
11. Schmitz, S.U., Grote, P., Herrmann, B.G., Mechanisms of long noncoding RNA function in development and disease. Cell. Mol. Life Sci. 73 (2016), 2491–2509.
12. Han, Y., Ye, J., Wu, D., Wu, P., Chen, Z., Chen, J., et al. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer, 14, 2014, 932.
13. Rao, A.K.D.M., Rajkumar, T., Mani, S., Perspectives of long non-coding RNAs in cancer. Mol. Biol. Rep. 44:2 (2017), 203–218.
14. Huarte, M., The emerging role of lncRNAs in cancer. Nat. Med. 21 (2015), 1253–1261.
15. Schmidt, L.H., Spieker, T., Koschmieder, S., Schaffers, S., Humberg, J., Jungen, D., et al. The long noncoding malat-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J. Thorac. Oncol. 6:12 (2011), 1984–1992.
16. Fellenberg, J., Bernd, L., Delling, G., Witte, D., Zahlten-Hinguranage, A., Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod. Pathol. 20:10 (2007), 1085–1094.
17. Fawzy, M.S., Toraih, E.A., Abdallah, H.Y., Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1): a molecular predictor of poor survival in glioblastoma multiforme in Egyptian patients. Egypt. J. Med. Hum. Genet. 18 (2017), 231–239.
18. Lin, R., Maeda, S., Liu, C., Karin, M., Edgington, T.S., A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26 (2007), 851–858.
19. Brown, J.A., Kinzig, C.G., DeGregorio, S.J., Steitz, J.A., Methyltransferase-like protein 16 binds the 3’-terminal triple helix of MALAT1 long noncoding RNA. Proc. Natl. Acad. Sci. U. S. A. 113:49 (2016), 14013–14018.
20. Zong, X., Nakagawa, S., Freier, S.M., Fei, J., Ha, T., Prasanth, S.G., et al. Natural antisense RNA promotes 3′ end processing and maturation of MALAT1 lncRNA. Nucleic Acids Res. 44:6 (2016), 2898–2908.
21. Wilusz, J.E., Freier, S.M., Spector, D.L., 3’ end processing of a long nuclear-retained non-coding RNA yields a tRNA-like cytoplasmic RNA. Cell 135:5 (2008), 919–932.
22. Lovet, J.M., Fuster, J., Bruix, J., The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10:2 (2004), S115–20.
23. Toraih, E.A., Mohammed, E.A., Farrag, S., Ramsis, N., Hosny, S., Pilot Study of Serum MicroRNA-21 as a Diagnostic and Prognostic Biomarker in Egyptian Breast Cancer Patients. Mol. Diagn. Ther. 19 (2015), 179–190.
24. Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55 (2009), 611–622.
25. Toraih, E.A., Fawzy, M.S., Mohammed, E.A., Hussein, M.H., El-labban MM. MicroRNA-196a2 biomarker and targetome network analysis in solid tumors. Mol. Diagn. Ther. 20:6 (2016), 559–577.
26. McCune, B., Mefford, M.J., PC-ORD. Multivariate Analysis of Ecological Data. Version 6. 2011, MjM Software, Gleneden Beach, Oregon, U.S.A.
27. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 8:5 (2010), 336–341.
28. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al. meta-analysis of observational studies in epidemiology: A proposal for reporting meta-analysis Of observational studies in epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012.
29. Yang, X., Xie, X., Xiao, Y., Xie, R., Hu, C.J., Tang, B., et al. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 360:2 (2015), 119–124.
30. Chen, L., Yao, H., Wang, K., Liu, X., Long non-coding RNA MALAT1 regulates ZEB1 expression by sponging miR-143-3p and promotes hepatocellular carcinoma progression. J. Cell. Biochem., 2017, 10.1002/jcb.26158.
31. Li, J., Yang, H., Cai, X., Huang, Y.-B., Shen, S.-Q., Wen, D.-Y., et al. Clinical value and function of lncRNA MALAT1 in hepatocellular carcinoma : A comprehensive study with original detection, meta-analysis and in vitro verification. Int. J. Clin. Exp. Pathol. 9:8 (2016), 7982–7994.
32. Konishi, H., Ischikawa, D., Yamamoto, Y., Arita, T., Shoda, K., Hiramoto, H., et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci. 107:2 (2016), 149–154.
33. Huang, Z., Huang, L., Shen, S., Li, J., Lu, H., Mo, W., et al. Sp1 cooperates with Sp3 to upregulate MALAT1 expression in human hepatocellular carcinoma. Oncol. Rep. 34:5 (2015), 2403–2412.
34. Lai, M.C., Yang, Z., Zhou, L., Zhu, Q.Q., Xie, H.Y., Zhang, F., et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med. Oncol. 29:3 (2012), 1810–1816.
35. Toraih, E.A., Fawzy, M.S., El-Falouji, A.I., Hamed, E.O., Nemr, N.A., Hussein, M.H., et al. Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer. Mol. Med. 22 (2016), 653–663.
36. Prabhakar, B., Zhong, X., Rasmussen, T.P., Exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases. Yale J. Biol. Med. 90:1 (2017), 73–86.
37. Lin, R., Maeda, S., Liu, C., Karin, M., Edgington, T.S., A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 26 (2007), 851–858.
38. Zhang, T.H., Liang, L.Z., Liu, X.L., Wu, J.N., Su, K., Chen, J.Y., et al. Long non-coding RNA MALAT1 interacts with miR-124 and modulates tongue cancer growth by targeting JAG1. Oncol. Rep. 37:4 (2017), 2087–2094.
39. Guo, F., Yu, F., Wang, J., Li, Y., Li, Y., Li, Z., et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer. Biomed. Rep. 3:3 (2015), 309–312.
40. Weber, D.G., Johnen, G., Casjens, S., Bryk, O., Pesch, B., Jockel, K.H., et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res. Notes, 6, 2013, 518.
41. Ren, S., Wang, F., Shen, J., Sun, Y., Xu, W., Lu, J., et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur. J. Cancer 49:13 (2013), 2949–2959.
42. Kishikawa, T., Otsuka, M., Ohno, M., Yoshikawa, T., Takata, A., Koike, K., Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J. Gastroenterol. 21 (2015), 8527–8540.
43. Schwarzenbach, H., Circulating nucleic acids as biomarkers in breast cancer. BCR, 15(5), 2013, 211.
44. Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., et al. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. Mol. Cancer Ther. 16:4 (2017), 739–751.
45. Huang, X., Gollin, S.M., Raja, S., Godfrey, T.E., High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc. Natl. Acad. Sci. U. S. A. 99:17 (2002), 11369–11374.
46. Liu, Y., Pan, S., Liu, L., Zhai, X., Liu, J., Wen, J., et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One, 7, 2012, e35145.
47. Koshimizu, T.A., Fujiwara, Y., Sakai, N., Shibata, K., Tsuchiya, H., Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line. Life Sci. 2010:86 (2010), 455–460.
48. Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., et al. TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin. Cancer Res. 20:6 (2014), 1531–1541.
49. Zhao, Y., Yang, Y., Trovik, J., Sun, K., Zhou, L., Jiang, P., et al. A novel wnt regulatory axis in endometrioid endometrial cancer. Cancer Res. 74:18 (2014), 5103–5117.
50. Liu, J., Wu, W., Jin, J., A novel mutation in SIRT1-AS leading to a decreased risk of HCC. Oncol. Rep. 34 (2015), 2343–2350.
51. Yuan, P., Cao, W., Zang, Q., Li, G., Guo, X., Fan, J., The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem. Biophys. Res. Commun. 478:3 (2016), 1067–1073.
52. Zhang, Y., Chen, Z., Li, M.J., Guo, H.Y., Jing, N.C., Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. Biomed. Pharmacother. 85 (2017), 264–271.
53. Wu, L., Wang, X., Guo, Y., Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. Exp. Ther. Med. 13:6 (2017), 3055–3060.
54. Hu, L., Wu, Y., Tan, D., Meng, H., Wang, K., Bai, Y., et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res., 34, 2015, 7.
55. Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 73:3 (2013), 1180–1189.
56. Arun, G., Diermeier, S., Akerman, M., Chang, K.C., Wilkinson, J.E., Hearn, S., et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 30 (2016), 34–51.
57. Hou, Z., Xu, X., Zhou, L., Fu, X., Tao, S., Zhou, J., et al. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. Tumour Biol., 39(7), 2017 1010428317718135.
58. Sun, R., Qin, C., Jiang, B., Fang, S., Pan, X., Peng, L., et al. Down-regulation of MALAT1 inhibits cervical cancer cell invasion and metastasis by inhibition of epithelial-mesenchymal transition. Mol. Biosyst. 12 (2016), 952–962.
59. Liang, J., Liang, L., Ouyang, K., Li, Z., Yi. MALAT1 induces tongue cancer cells’ EMT and inhibits apoptosis through wnt/β-catenin signaling pathway. J. Oral Pathol. Med. 46:2 (2017), 98–105.
60. Huo, Y., Li, Q., Wang, X., Jiao, X., Zheng, J., Li, Z., et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2. Oncotarget 8:29 (2017), 46993–47006.
61. Hirata, H., Hinoda, Y., Shahryari, V., Deng, G., Nakajima, K., Tabatabai, Z.L., et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 75:7 (2015), 1322–1331.
62. Huang, J.K., Ma, L., Song, W.H., Lu, B.Y., Huang, Y.B., Dong, H.M., et al. LncRNA-MALAT1 Promotes Angiogenesis of Thyroid Cancer by Modulating Tumor-Associated Macrophage FGF2 Protein Secretion. J. Cell. Biochem., 2017, 10.1002/jcb.26153 [Epub ahead of print].
63. Tee, A.E., Liu, B., Song, R., Li, J., Pasquier, E., Cheung, B.B., et al. The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. Oncotarget 7 (2016), 8663–8675.
64. Li, Z., Xu, C., Ding, B., Gao, M., Wei, X., Ji, N., Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101. J. Neurooncol. 134:1 (2017), 19–28.
65. Fu, Z., Luo, W., Wang, J., Peng, T., Sun, G., Shi, J., et al. Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma. Biochem. Biophys. Res. Commun. 492:3 (2017), 480–486.
66. Chen, W., Xu, X.K., Li, J.L., Kong, K.K., Li, H., Chen, C., et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget 8:14 (2017), 22783–22799.
67. Jin, C., Yan, B., Lu, Q., Lin, Y., Ma, L., The role of MALAT1/miR-1/slug axis on radioresistance in nasopharyngeal carcinoma. Tumour Biol. 37 (2016), 4025–4033.
68. Feng, T., Shao, F., Wu, Q., Zhang, X., Xu, D., Qian, K., et al. miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget 7:13 (2016), 16205–16216.
69. Wang, Y., Zhou, Y., Yang, Z., Chen, B., Huang, W., Liu, Y., Zhang, Y., MiR-204/ZEB2 axis functions as key mediator for MALAT1-induced epithelial-mesenchymal transition in breast cancer. Tumour Biol., 39(7), 2017 1010428317690998.
70. Bamodu, O.A., Huang, W.C., Lee, W.H., Wu, A., Wang, L.S., Hsiao, M., et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer, 16, 2016, 160.
71. Wang, X., Li, M., Wang, Z., Han, S., Tang, X., Ge, Y., et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J. Biol. Chem. 290 (2015), 3925–3935.
72. Li, J., Gao, J., Tian, W., Li, Y., Zhang, J., Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297. Cancer Cell. Int., 17, 2017, 44.
73. Liu, D., Zhu, Y., Pang, J., Weng, X., Feng, X., Guo, Y., Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. J. Cell. Biochem., 2017, 10.1002/jcb.26297 [Epub ahead of print].
74. Dou, C., Sun, L., Jin, X., Han, M., Zhang, B., Li, T., Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. Tumour Biol., 39(4), 2017, 1010428317697572.
75. Yuan, P., Cao, W., Zang, Q., Li, G., Guo, X., Fan, J., The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. Biochem. Biophys. Res. Commun. 478:3 (2016), 1067–1073.
76. Tan, X., Huang, Z., Li, X., Long non-coding RNA MALAT1 interacts with miR-204 to modulate human hilar cholangiocarcinoma proliferation, migration, and invasion by targeting CXCR4. J. Cell. Biochem. 118:11 (2017), 3643–3653.
77. Wang, S.H., Zhang, W.J., Wu, X.C., Weng, M.Z., Zhang, M.D., Cai, Q., et al. The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer. J. Cell. Mol. Med. 20:12 (2016), 2299–2308.
78. Zhang, Y., Tang, X., Shi, M., Wen, C., Shen, B., MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 483:2 (2017), 816–822.
79. Zhang, L., Niyazi, H.E., Zhao, H.R., Cao, X.P., Abudula, M.N., Ye, W.J., et al. Effects of miRNA-143 and the non-coding RNA MALAT1 on the pathogenesis and metastasis of HeLa cells. Genet. Mol. Res., 16(1), 2017.
80. Liu, S., Song, L., Zeng, S., Zhang, L., MALAT1-miR-124-RBG2 axis is involved in growth and invasion of HR-HPV-positive cervical cancer cells. Tumour Biol. 37 (2016), 633–640.
81. Li, Q., Zhang, C., Chen, R., Xiong, H., Qiu, F., Liu, S., et al. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. Cancer Lett. 383:1 (2016), 28–40.
82. Xiao, H., Tang, K., Liu, P., Chen, K., Hu, J., Zeng, J., et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget 6 (2015), 38005–38015.
83. Han, Y., Liu, Y., Zhang, H., Wang, T., Diao, R., Jiang, Z., et al. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT1. FEBS Lett. 587:23 (2013), 3875–3882.
84. Liu, K., Huang, J., Ni, J., Song, D., Ding, M., Wang, J., et al. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle. 16:6 (2017), 578–587.
85. Chen, R., Wang, G., Zheng, Y., Hua, Y., Cai, Z., Long non-coding RNAs in osteosarcoma. Oncotarget 8:12 (2017), 20462–20475.
86. Sun, Y., Cheng, H., Wang, G., Yu, G., Zhang, D., Wang, Y., et al. Deregulation of miR-183 promotes melanoma development via lncRNA MALAT1 regulation and ITGB1 signal activation. Oncotarget 8:2 (2017), 3509–3518.
87. Bi, S., Wang, C., Li, Y., Zhang, W., Zhang, J., Lv, Z., et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumour Biol., 39(5), 2017, 1010428317699796.